A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma
Summary
This is a Phase 2a, randomized multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma.
Timeline
- Start
- 2006-11
- Primary completion
- 2007-08
- Completion
- 2008-01
Outcome
Missed primary endpoint
registry analysis (superiority or other test); PLACEBO vs MEDI528 9 mg/kg; p = 0.168; Univariate 2-sample t-test NCT00394654 ↗
registry analysis (superiority or other test); PLACEBO vs MEDI528 9 mg/kg; p = 0.254; Univariate 2-sample t-test NCT00394654 ↗
registry analysis (superiority or other test); PLACEBO vs MEDI528 9 mg/kg; p = 0.677; Univariate 2-sample t-test NCT00394654 ↗
registry analysis (superiority or other test); PLACEBO vs MEDI528 9 mg/kg; p = 0.318; Univariate 2-sample t-test NCT00394654 ↗
registry analysis (superiority or other test); PLACEBO vs MEDI528 9 mg/kg; p = 0.798; Univariate 2-sample t-test NCT00394654 ↗
registry analysis (superiority or other test); PLACEBO vs MEDI528 9 mg/kg; p = 0.766; Univariate 2-sample t-test NCT00394654 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENOKIZUMAB | Monoclonal antibody | 9 mg/kg | Intravenous |